EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Programmed Cell Death in Cancer

Yuang Wei, William Hankey, Dongliang Xu, Fuwen Yuan

MedComm · 2025-09 · 6 (9)

DOI: 10.1002/mco2.70357 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 31.08.2025. Verfasst von Yuang Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine Shanghai China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 370 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Shenkang Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains the most lethal disease globally, despite the significant progress made in early screening, surgery, and therapeutic development in recent decades. Programmed cell death (PCD) is a genetically regulated process essential for eliminating aberrant cells, yet its dysregulation drives tumorigenesis and therapy resistance. In this review, we present a complete discovery timeline of them and comprehensively synthesize the roles and mechanisms of major PCD forms, such as apoptosis, necroptosis, autophagy, pyroptosis, ferroptosis, and cuproptosis, across diverse cancer types. We not only detail the molecular mechanisms, dual functions, and alterations of these PCD modalities in cancers, but also summarize their interconnections and intrinsic crosstalk. Furthermore, we comprehensively discuss how diverse therapies, including chemotherapy, radiotherapy, immunotherapy, targeted agents, and hormone therapy, engage and manipulate specific PCD pathways, revealing the involvement of PCD in cancer treatment mechanisms. This review integrates extensive preclinical and clinical evidence on PCD‐targeted therapies with an in‐depth focus on ferroptosis, including its regulatory networks and therapeutic relevance. Special emphasis is placed on prostate cancer, highlighting the PCD‐based translational opportunities in this common malignancy. Taken together, we provide novel insights into the complex interplay between PCD and cancer biology and offer a framework for developing precision oncology therapies.

Schlagwörter

Stichwörter der Autor:innen

anticancer therapycancerferroptosisprogrammed cell deathprostate cancer

Autor:innen und Institutionen

  • Cancer Research Center School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine Shanghai China.
  • Urology Centre Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China.
  • Surgical Institute of Integrative Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China.
  • Shanghai Key Laboratory of Traditional Chinese Clinical Medicine Shanghai China.
  • Department of Genetics The University of North Carolina At Chapel Hill Chapel Hill North Carolina USA.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Shenkang Hospital Development Center

Zitieren

APA

Wei, Y., Hankey, W., Xu, D., & Yuan, F. (2025). Programmed Cell Death in Cancer. MedComm, 6(9). https://doi.org/10.1002/mco2.70357

Vancouver

Wei Y, Hankey W, Xu D, Yuan F. Programmed Cell Death in Cancer. MedComm. 2025;6(9). doi:10.1002/mco2.70357

BibTeX
@article{Wei2025,
  author = {Wei, Yuang and Hankey, William and Xu, Dongliang and Yuan, Fuwen},
  title = {Programmed Cell Death in Cancer},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {9},
  doi = {10.1002/mco2.70357}
}
Kostenlos starten →